BRPI0409322A - método para preparação de conjugados de proteìna especìficos de local - Google Patents

método para preparação de conjugados de proteìna especìficos de local

Info

Publication number
BRPI0409322A
BRPI0409322A BRPI0409322-4A BRPI0409322A BRPI0409322A BR PI0409322 A BRPI0409322 A BR PI0409322A BR PI0409322 A BRPI0409322 A BR PI0409322A BR PI0409322 A BRPI0409322 A BR PI0409322A
Authority
BR
Brazil
Prior art keywords
polymer
protein
site
conjugate
preparing
Prior art date
Application number
BRPI0409322-4A
Other languages
English (en)
Inventor
Kenneth Hinds
Danny Lewis
Paul Schmidt
Kathlenn M Campbell
Original Assignee
Pr Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pr Pharmaceuticals Inc filed Critical Pr Pharmaceuticals Inc
Priority to BR122016021907A priority Critical patent/BR122016021907B8/pt
Publication of BRPI0409322A publication Critical patent/BRPI0409322A/pt
Publication of BRPI0409322B1 publication Critical patent/BRPI0409322B1/pt
Publication of BRPI0409322B8 publication Critical patent/BRPI0409322B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

"MéTODO PARA PREPARAçãO DE CONJUGADOS DE PROTEìNA ESPECìFICOS DE LOCAL". A invenção refere-se a um método de etapa única, para preparar rapidamente e eficientemente conjugados de proteína-polímero, inclusive um conjugado de insulina-polímero. De acordo com o método da presente invenção, uma proteína e polímero hidrofílico são postos em contato na presença de pelo menos um solvente orgânico e pelo menos um quelador metálico, sob condições que promovem a formação de um conjugado da proteína e polímero. Desse modo, a invenção está voltada para a modificação específica de local de proteínas selecionadas, tal como insulina, com poli(etilenoglicol) no resíduo PheB1. A invenção também põe à disposição uma formulação farmacêutica para encapsular o conjugado em um polímero biodegradável.
BRPI0409322A 2003-04-11 2004-04-08 método para preparar um conjugado de insulina-polímero BRPI0409322B8 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122016021907A BR122016021907B8 (pt) 2003-04-11 2004-04-08 conjugado de insulina-peg, microesfera de poli(lactídioco-glicolídio), formulação de liberação de droga, e uso

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46236403P 2003-04-11 2003-04-11
PCT/US2004/010995 WO2004091494A2 (en) 2003-04-11 2004-04-08 Method for preparation of site-specific protein conjugates

Publications (3)

Publication Number Publication Date
BRPI0409322A true BRPI0409322A (pt) 2006-04-25
BRPI0409322B1 BRPI0409322B1 (pt) 2017-02-07
BRPI0409322B8 BRPI0409322B8 (pt) 2021-05-25

Family

ID=33299938

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0409322A BRPI0409322B8 (pt) 2003-04-11 2004-04-08 método para preparar um conjugado de insulina-polímero
BR122016021907A BR122016021907B8 (pt) 2003-04-11 2004-04-08 conjugado de insulina-peg, microesfera de poli(lactídioco-glicolídio), formulação de liberação de droga, e uso

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122016021907A BR122016021907B8 (pt) 2003-04-11 2004-04-08 conjugado de insulina-peg, microesfera de poli(lactídioco-glicolídio), formulação de liberação de droga, e uso

Country Status (9)

Country Link
US (2) US9040664B2 (pt)
EP (2) EP1613272B1 (pt)
JP (3) JP2006522816A (pt)
CN (2) CN101514223B (pt)
AU (2) AU2004229461A1 (pt)
BR (2) BRPI0409322B8 (pt)
CA (2) CA3074393A1 (pt)
DK (1) DK2599502T3 (pt)
WO (1) WO2004091494A2 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2427092T3 (es) 2003-04-10 2013-10-28 Evonik Corporation Un método para la producción de micropartículas a base de emulsión
DK2599502T3 (en) 2003-04-11 2017-04-18 Antriabio Inc Process for Preparation of Site-Specific Protein Conjugates
CN1852687B (zh) 2003-07-15 2014-01-22 赢创有限公司 控释组合物的制备方法
JP5165240B2 (ja) 2003-07-23 2013-03-21 ピーアール ファーマシューティカルズ， インコーポレイテッド 徐放組成物
DK1648933T3 (da) * 2003-07-25 2009-09-07 Conjuchem Biotechnologies Inc Langvarige insulinderivater og fremgangsm der
WO2005039641A2 (en) * 2003-10-15 2005-05-06 The Regents Of The University Of California Biomacromolecule polymer conjugates
TWI376234B (en) 2005-02-01 2012-11-11 Msd Oss Bv Conjugates of a polypeptide and an oligosaccharide
EP3222142A1 (en) * 2006-02-28 2017-09-27 Kodiak Sciences Inc. Acryloyloxyethylphosphorylcholine containing polymer conjugates and their preparation
US8299015B2 (en) * 2006-07-25 2012-10-30 Lipoxen Technologies Limited Derivatisation of granulocyte colony-stimulating factor
PL2054074T3 (pl) * 2006-08-04 2015-03-31 Prolong Pharmaceuticals Llc Zmodyfikowana erytropoetyna
TWI451876B (zh) 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
JP5766118B2 (ja) * 2008-09-11 2015-08-19 ウェルズ ファーゴ バンク ナショナル アソシエイション ポリマー性アルファ−ヒドロキシアルデヒドおよびケトン反応剤ならびに抱合方法
WO2010033240A2 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
MX2011009803A (es) * 2009-03-20 2011-09-30 Hanmi Holdings Co Ltd Metodo para preparar un polipeptido conjugado fisiologicamente activo en un sitio especifico.
GB0905555D0 (en) * 2009-03-31 2009-05-13 Peptcell Ltd Pharmaceutical agent
CN102612362A (zh) 2009-08-05 2012-07-25 皮里斯股份公司 脂质运载蛋白突变蛋白的控制释放制剂
WO2011041376A1 (en) * 2009-09-30 2011-04-07 Prolong Pharmaceuticals Modified granulocyte colony stimulating factor (g-csf)
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
US9981017B2 (en) 2010-04-02 2018-05-29 Hanmi Science Co., Ltd. Insulin conjugate using an immunoglobulin fragment
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
KR20130049671A (ko) * 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
AR090281A1 (es) 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
AR090843A1 (es) * 2012-05-09 2014-12-10 Lilly Co Eli Tratamiento para diabetes comorbida con enfermedad renal cronica
CN104620093B (zh) * 2012-08-23 2018-04-20 干细胞技术公司 用于快速可逆生物分子标记的组合物和方法
WO2015035342A2 (en) 2013-09-08 2015-03-12 Oligasis Llc Factor viii zwitterionic polymer conjugates
WO2015130963A2 (en) 2014-02-27 2015-09-03 Xenetic Biosciences, Inc. Compositions and methods for administering insulin or insulin-like protein to the brain
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US9439864B2 (en) * 2014-07-07 2016-09-13 Antriabio, Inc. Solvent extraction from biodegradable microparticles
JP2017525370A (ja) 2014-08-21 2017-09-07 ザ ジェネラル ホスピタル コーポレイション 腫瘍壊死因子スーパーファミリーおよびｔｎｆ様リガンドムテインならびに腫瘍壊死因子スーパーファミリーおよびｔｎｆ様リガンドムテインを調製および使用する方法
KR20210013299A (ko) 2014-10-17 2021-02-03 코디악 사이언시스 인코포레이티드 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
US20160151511A1 (en) * 2014-12-02 2016-06-02 Antriabio, Inc. Proteins and protein conjugates with increased hydrophobicity
WO2016196017A1 (en) 2015-06-04 2016-12-08 Antriabio, Inc. Amine pegylation methods for the preparation of site-specific protein conjugates
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
EP3758737A4 (en) 2018-03-02 2022-10-12 Kodiak Sciences Inc. IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2022138701A1 (ja) 2020-12-25 2022-06-30 富士フイルム株式会社 電磁波シールド材、電子部品および電子機器

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
DE2930542A1 (de) 1979-07-27 1981-02-12 Hoechst Ag Neue insulinderivate und verfahren zu ihrer herstellung
US5102872A (en) 1985-09-20 1992-04-07 Cetus Corporation Controlled-release formulations of interleukin-2
US5349052A (en) 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
IE912365A1 (en) 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5650234A (en) 1994-09-09 1997-07-22 Surface Engineering Technologies, Division Of Innerdyne, Inc. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US5942253A (en) 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
DE69819145T2 (de) 1997-04-17 2004-08-19 Amgen Inc., Thousand Oaks Bioabbaubare mikropartikeln mit verzögerter wirkstofffreisetzung
US6323311B1 (en) * 1999-09-22 2001-11-27 University Of Utah Research Foundation Synthesis of insulin derivatives
DK1455839T3 (da) 1999-10-08 2013-05-06 Nektar Therapeutics Heterobifunktioneller poly(ethylenglycol)-derivater og fremgangsmåder til fremstilling heraf
US6586398B1 (en) * 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
CN1507357A (zh) 2000-10-31 2004-06-23 PRҩƷ���޹�˾ 提高生物活性分子传递的方法和组合物
AU2002239279A1 (en) 2000-11-20 2002-06-03 Pr Pharmaceuticals, Inc. Oral nanosphere delivery
CZ20033182A3 (cs) * 2001-05-21 2004-09-15 Nektar Therapeutics Inzulínový prostředek a způsob podávání inzulínu
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
DK2599502T3 (en) 2003-04-11 2017-04-18 Antriabio Inc Process for Preparation of Site-Specific Protein Conjugates
GB201107664D0 (en) 2011-05-09 2011-06-22 Univ Leuven Kath Sensor for detecting liquid spilling

Also Published As

Publication number Publication date
WO2004091494A3 (en) 2006-02-09
JP2010248241A (ja) 2010-11-04
EP2599502A3 (en) 2014-07-30
BRPI0409322B8 (pt) 2021-05-25
BR122016021907B1 (pt) 2018-01-09
AU2004229461A1 (en) 2004-10-28
BR122016021907B8 (pt) 2021-07-27
EP1613272A4 (en) 2010-06-16
JP2006522816A (ja) 2006-10-05
BRPI0409322B1 (pt) 2017-02-07
US20150216995A1 (en) 2015-08-06
US9040664B2 (en) 2015-05-26
CA2521381A1 (en) 2004-10-28
EP1613272A2 (en) 2006-01-11
CA3074393A1 (en) 2004-10-28
JP2013256498A (ja) 2013-12-26
EP2599502A2 (en) 2013-06-05
WO2004091494A2 (en) 2004-10-28
CN101514223B (zh) 2017-03-01
CN101514223A (zh) 2009-08-26
US20070083006A1 (en) 2007-04-12
CA2521381C (en) 2020-05-26
DK2599502T3 (en) 2017-04-18
AU2010212312B2 (en) 2012-05-17
CN1777440A (zh) 2006-05-24
AU2010212312A1 (en) 2010-09-02
EP2599502B1 (en) 2017-03-01
EP1613272B1 (en) 2013-12-18
US9789196B2 (en) 2017-10-17
JP5576200B2 (ja) 2014-08-20

Similar Documents

Publication Publication Date Title
BRPI0409322A (pt) método para preparação de conjugados de proteìna especìficos de local
AR009127A1 (es) Procedimiento de preparacion de nanoparticulas de metilideno malona, particulas que contienen eventualmente una o mas moleculas biologicamente activas y composiciones farmaceuticas que las contienen
BRPI0612654B8 (pt) método para conjugar um sacarídeo a uma proteína, e, conjugado sacarídeo-proteína
Qin et al. Three‐dimensional microfabrication of protein hydrogels via two‐photon‐excited thiol‐vinyl ester photopolymerization
BRPI0409185A (pt) formulações veterinárias anti-helmìnticas tópicas
BRPI9809791B8 (pt) compostos imuno efetores de fosfato de aminoalquil glucosamina e composições compreendendo os mesmos
BRPI0314831B8 (pt) composições farmacêuticas e composição de lipossoma peg compreendendo um conjugado, seus métodos de produção, kit e usos terapêuticos das ditas composições
BR0015596A (pt) Método de preparação de partìculas de uma substância, e, partìculas de uma substância
ECSP055710A (es) Composición antihelmíntica e inyectable mejoradora de crecimiento
AR040693A1 (es) Formulaciones parenterales
DK1317921T3 (da) Farmaceutisk sammensætning i form af en gel eller oplösning med dihydrotestosteron, fremgangsmåde til fremstilling og anvendelser heraf
BRPI0511966A (pt) composições farmacêuticas contendo polietileno glicol tendo um peso molecular menor do que 600 daltons
BRPI0309868B8 (pt) métodos de preparação de uma composição de reduzida fração conjugada inferior
EA200301250A1 (ru) Фармацевтические композиции, содержащие слаборастворимые и/или чувствительные к кислотам лекарственные средства и нейтрализованные кислотные полимеры
CO5090836A1 (es) 3s tetrahidro 3 furanil 1s, 2r 3 / 4 aminofenil sulfonil (isobutil) [amino]1 bencil 2/(fosfonooxi)propilcarbamato de calcio
BR0309546A (pt) Composto, composição farmacêutica que compreende o mesmo, processo para a sua preparação e utilização e método para tratamento profilático ou terapêutico de diabetes do tipo ii
PY0401585A (es) Formulaciones farmaceuticas liquidas de palonosetron
BR0315047A (pt) Composto, composição fermacêutica que compreende o mesmo, processo para a preparação da composição farmacêutica, utilização dos compostos, método de tratamento e processo para a preparação do composto
BR0116332A (pt) Processo para o aumento da estabilidade
BR0215187A (pt) Composições farmacêuticas que compreendem uma ciclosporina, um tensoativo hidrofìlico e um tensoativo lipofìlico
Lee et al. PEGylation to improve protein stability during melt processing
DE69924304D1 (de) N-palmitoylethanolamid-enthaltende pharmazeutische zusammensetzungen und deren verwendung in der veterinärmedizin
Henise et al. Autoclave sterilization of tetra‐polyethylene glycol hydrogel biomaterials with β‐eliminative crosslinks
DE60223542D1 (de) Zusammensetzung mit fulvestrant
BR9908195A (pt) Derivado do grupo b das estreptograminas, processo para a preparação do mesmo, composições farmacêuticas, e, associações de derivados de estreptograminas.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: ANTRIABIO, INC. (US)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: A61K 31/00

Ipc: A61K 38/28 (2006.01), A61K 47/48 (2006.01), A61K 9

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 47/60 (2017.01), A61K 9/50 (2006.01), A61K 38

B25A Requested transfer of rights approved
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/04/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2665 DE 01-02-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.